ESR1 mediated circ_0004018 suppresses angiogenesis in hepatocellular carcinoma via recruiting FUS and stabilizing TIMP2 expression

Exp Cell Res. 2021 Nov 15;408(2):112804. doi: 10.1016/j.yexcr.2021.112804. Epub 2021 Sep 3.

Abstract

Angiogenesis has been certified to account for tumor pathobiology. Circular RNAs (circRNAs) have been demonstrated to be involved in angiogenesis-related diseases, including hepatocellular carcinoma (HCC). Nevertheless, the regulatory roles of most circRNAs remain obscure. This study aims to uncover the function of hsa_circ_0004018 on angiogenesis in HCC. Firstly, quantitative real-time RT-PCR (RT-qPCR) analyzed that circ_0004018 was definitely down-regulated in HCC. Western blot analysis was conducted to detect the protein level of fused protein in sarcoma (FUS) and TIMP metallopeptidase inhibitor 2 (TIMP2). Functional assays were carried out to assess the impacts of circ_0004018 on HCC. From the experimental results, we found that overexpression of circ_0004018 significantly inhibited angiogenesis in HCC. The regulatory mechanism of circ_0004018 in HCC was determined by chromatin immunoprecipitation (ChIP), luciferase reporter assays and RNA immunoprecipitation (RIP) assay. Therefore, we proved that estrogen receptor 1 (ESR1) mediated circ_0004018 regulated TIMP2 by recruiting FUS. A series of rescue assays verified that circ_0004018 participated in angiogenesis in HCC via modulating TIMP2. In summary, this paper disclosed that ESR1 activated circ_0004018 inhibited angiogenesis in HCC via binding to FUS and stabilizing TIMP2 expression.

Keywords: Angiogenesis; FUS; Hepatocellular carcinoma; TIMP2; hsa_circ_0004018.

MeSH terms

  • Animals
  • Apoptosis / genetics
  • Carcinoma, Hepatocellular / genetics*
  • Carcinoma, Hepatocellular / pathology
  • Cell Line, Tumor
  • Cell Proliferation / genetics
  • Estrogen Receptor alpha / genetics*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Liver Neoplasms / genetics
  • Liver Neoplasms / pathology
  • Mice
  • Neovascularization, Pathologic / genetics*
  • Neovascularization, Pathologic / pathology
  • RNA, Circular / genetics*
  • RNA-Binding Protein FUS / genetics*
  • Tissue Inhibitor of Metalloproteinase-2 / genetics*
  • Xenograft Model Antitumor Assays

Substances

  • ESR1 protein, human
  • Estrogen Receptor alpha
  • FUS protein, human
  • RNA, Circular
  • RNA-Binding Protein FUS
  • TIMP2 protein, human
  • Tissue Inhibitor of Metalloproteinase-2